Pharmaceutical giant Pfizer Inc. (PFE) on Monday announced that it is ending the development of its experimental weight loss drug after one patient in its trial group reported a potential drug-induced ...

Pfizer has terminated the development of its oral obesity candidate danuglipron after a patient on a clinical trial with the drug suffered a liver injury. The oral glucagon-like peptide-1 receptor ...

Stimulating a receptor in adipocytes enhanced energy expenditure and caused sustained weight loss in mice, offering targets ...

Doer Biologics begins patient dosing in phase 2 study of DR10624 to treat metabolic dysfunction-associated steatotic liver disease and MASH: Hangzhou, China Thursday, April 24, 20 ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a group of drugs used to treat type 2 diabetes and sometimes obesity. GLP-1 RAs are very effective at lowering blood sugar levels.

Drug-induced liver injury was reported in 1 asymptomatic patient ... to discontinue the clinical development program for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist being ...

In one study, once-daily danuglipron resulted in one patient who experienced drug-related elevated liver enzymes.

4 Glucagon Receptor Activation ... Transient, self-resolving elevations in liver enzymes were rare, affecting approximately 1% of treated participants without leading to persistent hepatic ...

Mr. Kim continued, "Additionally, activation of either the GLP-1 or glucagon receptors is known to increase heart rate. As a result, dual agonists that simultaneously activate both receptors may ...

Pfizer (PFE) announced the decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was ...